JP7369132B2 - ５－ヘテロアリール置換イミダゾール－３－カルボキサミドならびにその調製および使用の方法 - Google Patents
５－ヘテロアリール置換イミダゾール－３－カルボキサミドならびにその調製および使用の方法 Download PDFInfo
- Publication number
- JP7369132B2 JP7369132B2 JP2020544501A JP2020544501A JP7369132B2 JP 7369132 B2 JP7369132 B2 JP 7369132B2 JP 2020544501 A JP2020544501 A JP 2020544501A JP 2020544501 A JP2020544501 A JP 2020544501A JP 7369132 B2 JP7369132 B2 JP 7369132B2
- Authority
- JP
- Japan
- Prior art keywords
- unsubstituted
- alkyl
- optionally substituted
- cancer
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862634656P | 2018-02-23 | 2018-02-23 | |
| US62/634,656 | 2018-02-23 | ||
| PCT/US2019/019129 WO2019165192A1 (en) | 2018-02-23 | 2019-02-22 | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021516674A JP2021516674A (ja) | 2021-07-08 |
| JP2021516674A5 JP2021516674A5 (https=) | 2022-02-24 |
| JPWO2019165192A5 JPWO2019165192A5 (https=) | 2022-02-24 |
| JP7369132B2 true JP7369132B2 (ja) | 2023-10-25 |
Family
ID=65812386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544501A Active JP7369132B2 (ja) | 2018-02-23 | 2019-02-22 | ５－ヘテロアリール置換イミダゾール－３－カルボキサミドならびにその調製および使用の方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10934297B2 (https=) |
| EP (1) | EP3755696B1 (https=) |
| JP (1) | JP7369132B2 (https=) |
| KR (1) | KR102861944B1 (https=) |
| CN (1) | CN112020501A (https=) |
| AU (1) | AU2019224075A1 (https=) |
| BR (1) | BR112020017087A2 (https=) |
| CA (1) | CA3091913A1 (https=) |
| CL (1) | CL2020002177A1 (https=) |
| EA (1) | EA202092002A1 (https=) |
| ES (1) | ES2945558T3 (https=) |
| IL (1) | IL276814A (https=) |
| MA (1) | MA51908A (https=) |
| MX (1) | MX2020008852A (https=) |
| PE (1) | PE20211447A1 (https=) |
| PH (1) | PH12020551300A1 (https=) |
| SG (1) | SG11202008029UA (https=) |
| WO (1) | WO2019165192A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019224075A1 (en) | 2018-02-23 | 2020-09-10 | Samumed, Llc | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof |
| PT3790873T (pt) * | 2018-05-07 | 2022-05-11 | Acraf | Compostos de 1h-indazole-3-carboxamida como inibidores da glicogénio sintase cinase 3 beta |
| JP7444458B2 (ja) * | 2018-09-21 | 2024-03-06 | 学校法人福岡大学 | プリオン病治療薬 |
| JP2023506257A (ja) * | 2019-12-16 | 2023-02-15 | コリア リサーチ インスティチュート オブ ケミカル テクノロジー | 新規なインダゾール誘導体及びその用途 |
| WO2021120890A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Pyrazolyl derivatives useful as anti-cancer agents |
| AU2024301960A1 (en) * | 2023-06-14 | 2026-01-22 | Prothena Biosciences Limited | Bicyclic heteroaromatic compounds for treating neurological disorders |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006504711A (ja) | 2002-10-02 | 2006-02-09 | サノフィ−アベンティス | インダゾールカルボキサミド誘導体、それらの製造法ならびにｃｄｋ１、ｃｄｋ２およびｃｄｋ４阻害剤としての用途 |
| JP2014526510A (ja) | 2011-09-14 | 2014-10-06 | サミュメッド リミテッド ライアビリティ カンパニー | インダゾール−３−カルボキサミドおよびＷＮＴ／β−カテニンシグナル伝達経路阻害剤としてのそれらの使用 |
| WO2016040182A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof |
| JP2017508763A (ja) | 2014-03-20 | 2017-03-30 | サミュメッド リミテッド ライアビリティ カンパニー | ５−置換インダゾール−３−カルボキサミドならびにその調製および使用の方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4164559A (en) | 1977-09-21 | 1979-08-14 | Cornell Research Foundation, Inc. | Collagen drug delivery device |
| US4474752A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| US6440102B1 (en) | 1998-07-23 | 2002-08-27 | Durect Corporation | Fluid transfer and diagnostic system for treating the inner ear |
| DE19853299C2 (de) | 1998-11-19 | 2003-04-03 | Thomas Lenarz | Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs |
| US6120484A (en) | 1999-02-17 | 2000-09-19 | Silverstein; Herbert | Otological implant for delivery of medicament and method of using same |
| US6967023B1 (en) | 2000-01-10 | 2005-11-22 | Foamix, Ltd. | Pharmaceutical and cosmetic carrier or composition for topical application |
| YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| US6648873B2 (en) | 2001-09-21 | 2003-11-18 | Durect Corp. | Aural catheter system including anchor balloon and balloon inflation device |
| GB0218625D0 (en) * | 2002-08-10 | 2002-09-18 | Astex Technology Ltd | Pharmaceutical compounds |
| MXPA05003317A (es) | 2002-09-25 | 2005-07-05 | Memory Pharm Corp | Indazoles, benzotiazoles y benzoisotiazoles asi como preparacion y usos de los mismos. |
| US7008953B2 (en) | 2003-07-30 | 2006-03-07 | Agouron Pharmaceuticals, Inc. | 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| FR2867778B1 (fr) * | 2004-03-16 | 2006-06-09 | Sanofi Synthelabo | Utilisation de derives d'indazolecarboxamides pour la preparation d'un medicament destine au traitement et a la prevention du paludisme |
| NZ550534A (en) | 2004-03-25 | 2009-07-31 | Memory Pharm Corp | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof |
| UA93348C2 (ru) * | 2004-03-25 | 2011-02-10 | Меморі Фармас'Ютікалз Корпорейшн | Индазолы, бензотиазолы, бензоизотиазолы, их получение и применение |
| WO2011050245A1 (en) * | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
| CN103889976A (zh) * | 2011-08-12 | 2014-06-25 | 弗·哈夫曼-拉罗切有限公司 | 吲唑化合物、组合物及使用方法 |
| CA2860250C (en) * | 2012-02-21 | 2020-11-10 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
| PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| BR112018009252A2 (pt) | 2015-11-06 | 2018-11-06 | Samumed Llc | tratamento da osteoartrite |
| LT3464285T (lt) | 2016-06-01 | 2022-12-27 | Biosplice Therapeutics, Inc. | N-(5-(3-(7-(3-fluorfenil)-3h-imidazo[4,5-c]piridin-2-il)-1h-indazol-5-il)piridin-3-il)- 3-metilbutanamido gamybos būdas |
| CN110709082A (zh) * | 2016-10-21 | 2020-01-17 | 萨穆梅德有限公司 | 吲唑-3-甲酰胺的使用方法及其作为Wnt/β-连环蛋白信号传导途径抑制剂的用途 |
| AU2019224075A1 (en) | 2018-02-23 | 2020-09-10 | Samumed, Llc | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof |
-
2019
- 2019-02-22 AU AU2019224075A patent/AU2019224075A1/en not_active Abandoned
- 2019-02-22 BR BR112020017087-9A patent/BR112020017087A2/pt not_active IP Right Cessation
- 2019-02-22 PE PE2020001271A patent/PE20211447A1/es unknown
- 2019-02-22 MA MA051908A patent/MA51908A/fr unknown
- 2019-02-22 EA EA202092002A patent/EA202092002A1/ru unknown
- 2019-02-22 US US16/283,366 patent/US10934297B2/en active Active
- 2019-02-22 CN CN201980027314.1A patent/CN112020501A/zh active Pending
- 2019-02-22 JP JP2020544501A patent/JP7369132B2/ja active Active
- 2019-02-22 ES ES19711736T patent/ES2945558T3/es active Active
- 2019-02-22 CA CA3091913A patent/CA3091913A1/en active Pending
- 2019-02-22 MX MX2020008852A patent/MX2020008852A/es unknown
- 2019-02-22 EP EP19711736.9A patent/EP3755696B1/en active Active
- 2019-02-22 KR KR1020207027174A patent/KR102861944B1/ko active Active
- 2019-02-22 WO PCT/US2019/019129 patent/WO2019165192A1/en not_active Ceased
- 2019-02-22 SG SG11202008029UA patent/SG11202008029UA/en unknown
-
2020
- 2020-08-19 IL IL276814A patent/IL276814A/en unknown
- 2020-08-20 PH PH12020551300A patent/PH12020551300A1/en unknown
- 2020-08-24 CL CL2020002177A patent/CL2020002177A1/es unknown
- 2020-12-30 US US17/138,098 patent/US11713320B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006504711A (ja) | 2002-10-02 | 2006-02-09 | サノフィ−アベンティス | インダゾールカルボキサミド誘導体、それらの製造法ならびにｃｄｋ１、ｃｄｋ２およびｃｄｋ４阻害剤としての用途 |
| JP2014526510A (ja) | 2011-09-14 | 2014-10-06 | サミュメッド リミテッド ライアビリティ カンパニー | インダゾール−３−カルボキサミドおよびＷＮＴ／β−カテニンシグナル伝達経路阻害剤としてのそれらの使用 |
| JP2017508763A (ja) | 2014-03-20 | 2017-03-30 | サミュメッド リミテッド ライアビリティ カンパニー | ５−置換インダゾール−３−カルボキサミドならびにその調製および使用の方法 |
| WO2016040182A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019224075A1 (en) | 2020-09-10 |
| EP3755696B1 (en) | 2023-04-05 |
| ES2945558T3 (es) | 2023-07-04 |
| US20190263821A1 (en) | 2019-08-29 |
| CN112020501A (zh) | 2020-12-01 |
| EA202092002A1 (ru) | 2021-01-21 |
| US20220402921A1 (en) | 2022-12-22 |
| SG11202008029UA (en) | 2020-09-29 |
| BR112020017087A2 (pt) | 2020-12-22 |
| MA51908A (fr) | 2021-06-02 |
| EP3755696A1 (en) | 2020-12-30 |
| IL276814A (en) | 2020-10-29 |
| US10934297B2 (en) | 2021-03-02 |
| CL2020002177A1 (es) | 2021-01-08 |
| WO2019165192A1 (en) | 2019-08-29 |
| KR20200126393A (ko) | 2020-11-06 |
| JP2021516674A (ja) | 2021-07-08 |
| PH12020551300A1 (en) | 2021-10-25 |
| KR102861944B1 (ko) | 2025-09-26 |
| US11713320B2 (en) | 2023-08-01 |
| CA3091913A1 (en) | 2019-08-29 |
| MX2020008852A (es) | 2020-10-14 |
| PE20211447A1 (es) | 2021-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12281097B2 (en) | Isoquinolin-3-yl carboxamides and preparation and use thereof | |
| JP7369132B2 (ja) | ５－ヘテロアリール置換イミダゾール－３－カルボキサミドならびにその調製および使用の方法 | |
| JP7023243B2 (ja) | イソキノリン－３イル－カルボキサミドならびにその調製および使用の方法 | |
| US10759799B2 (en) | Indazole containing macrocycles and therapeutic uses thereof | |
| WO2017023988A1 (en) | 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof | |
| WO2017024015A1 (en) | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof | |
| WO2017023989A1 (en) | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof | |
| WO2017024004A1 (en) | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof | |
| WO2017024021A1 (en) | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof | |
| WO2016040188A1 (en) | 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof | |
| WO2017023984A1 (en) | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof | |
| WO2017024013A1 (en) | 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof | |
| WO2017023980A1 (en) | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof | |
| HK40005209B (en) | Isoquinolin-3-yl carboxamides and preparation and use thereof | |
| HK40005209A (en) | Isoquinolin-3-yl carboxamides and preparation and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20210514 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220215 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220215 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230130 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230201 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230427 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230629 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20230704 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230928 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231013 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7369132 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |